HBV News and Research

RSS

UTMB receives grant to combat highly-lethal hemorrhagic fever viruses

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Vanderbilt University Medical Center, Mapp Biopharmaceutical and Genevant Sciences Corp. have been awarded up to $35 million to advance the development of rapid-acting vaccines and broad-spectrum treatments of the highly-lethal hemorrhagic fever viruses Ebola and Marburg.

9 Apr 2019

Cellular protein could take on role of restriction factor for hepatitis B virus

Hepatitis B is a viral liver infection that can lead to acute or chronic conditions. Although there is a vaccine that offers protection against the virus, current treatments which prevent the virus from replicating are not curative for infected individuals.

8 Apr 2019

WHO guidelines for chronic hepatitis B fail to detect half of the patients in Ethiopia needing treatment

Current World Health Organization (WHO) guidelines for chronic hepatitis B (CHB) fail to detect half of the patients in need of treatment in Ethiopia, report scientists in the Journal of Hepatology, published by Elsevier.

29 Mar 2019

New strategy for potential treatment of HBV associated liver cancer

Researchers from Duke-NUS Medical School, Singapore General Hospital and Lion TCR have demonstrated that they were able to engineer HBV-specific T cells, a type of immune cells found in the body, to treat Hepatocellular carcinoma, a commonly occurring liver cancer.

28 Mar 2019

Current HBV genome sequences help deduce ancient human population movements into Australia

Australian researchers have used current hepatitis B virus (HBV) genome sequences to deduce ancient human population movements into Australia, adding weight to the theory that the mainland Aboriginal population separated from other early humans at least 59 thousand years ago and possibly entered the country near the Tiwi Islands.

19 Mar 2019

TGen and ABL sign agreement to distribute new TB test technology

n an important step toward eradicating tuberculosis, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has signed a licensing agreement with an international biomedical firm, Advanced Biological Laboratories, to market and distribute TGen's patented Next Generation Sequencing-based TB test technology.

19 Mar 2019

Antiviral treatment improves survival for kidney transplant recipients infected with HBV or HCV

Prior to the development of antiviral therapy, kidney transplant recipients infected with either hepatitis B or hepatitis C experienced poor outcomes.

15 Mar 2019

PNAS publishes results of pilot study for early detection of liver cancer

Today, Proceedings of the National Academy of Sciences published the results of a pilot study for early detection of liver cancer in a cohort of HBV carriers, who are at risk for developing this disease.

13 Mar 2019

FDA grants clearance to Hologic’s assay for detection of common sexually transmitted infections

Hologic, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its Aptima Mycoplasma genitalium assay, the first and only FDA-cleared test to detect this under-recognized but increasingly common sexually transmitted infection (STI).

23 Jan 2019

ECDC and WHO release latest data on HIV epidemic in the European Region

The European Centre for Disease Prevention and Control and the WHO Regional Office for Europe release the latest data on the HIV epidemic in the European Region, marking the 30th anniversary of World AIDS Day.

29 Nov 2018

First modeling system developed for testing age-specific human immune responses to vaccines

A team of scientists at Boston Children's Hospital has developed the first modeling system for testing age-specific human immune responses to vaccines -- outside the body. The practical, cost-effective new platform, using all human components, is expected to accelerate and de-risk the development, assessment and selection of vaccines.

20 Nov 2018

NIH researchers shed light on causes of HBV-associated acute liver failure

National Institutes of Health scientists and their collaborators found that hepatitis B virus-associated acute liver failure--a rare condition that can turn fatal within days without liver transplantation--results from an uncommon encounter between a highly mutated HBV variant and an unusual immune response in the patient's liver that is mainly sustained by antibody-producing B cells.

14 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Research reveals high stability of hepatitis B viruses

At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

30 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody

Harbour BioMed today announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.

20 Aug 2018